title: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
abstract: OBJECTIVE
  Studies conducted by the Eastern Cooperative Oncology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival in patients with stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC.
  
  
  METHODS
  Eligibility included previously untreated stage IIIB or IV NSCLC patients with a good performance status (PS). Paclitaxel (135 or 175 mg/m2) was administered by 24-hour infusion on day 1, followed by a 1-hour infusion of carboplatin on day 2 (300 mg/m2 or dosed to an area under the concentration-time curve [AUC] of 6 mg/mL.min). Treatment was repeated every 28 days for a total of six cycles. Hematopoietic growth factors were not routinely used.
  
  
  RESULTS
  Among 51 eligible patients, there were no complete and 14 partial responses, for an overall response rate of 27% (95% confidence interval [CI], 17% to 41%). The median progression-free survival time was 23.8 weeks (range, 12.1 to 73.9) and median survival time, 38 weeks. The survival rate at 1 year was 32%. Grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 47% and 3%, respectively, of the 184 treatment cycles administered. The most common nonhematologic toxicities included nausea and emesis, neuropathy, and arthralgia/myalgia.
  
  
  CONCLUSIONS
  Paclitaxel plus carboplatin is a moderately active regimen in patients with advanced NSCLC and warrants comparison with existing cisplatin-based regimens in a prospective randomized trial. The toxicities of this regimen are well tolerated in patients with a good PS.
authors.affiliation: Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA. david.johnson@mcmail.vanderbilt.edu
authors.forename: D H
authors.initials: DH
authors.lastname: Johnson
authors.forename: D M
authors.initials: DM
authors.lastname: Paul
authors.forename: K R
authors.initials: KR
authors.lastname: Hande
authors.forename: Y
authors.initials: Y
authors.lastname: Shyr
authors.forename: C
authors.initials: C
authors.lastname: Blanke
authors.forename: B
authors.initials: B
authors.lastname: Murphy
authors.forename: M
authors.initials: M
authors.lastname: Lewis
authors.forename: R F
authors.initials: RF
authors.lastname: De Vore
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D015996:Survival Rate
chemical_list: D016190:Carboplatin; D017239:Paclitaxel